It is the second recent study to show ivermectin didn’t improve patient outcomes for factors related to COVID-19 infection. Researchers analyzed 3,515 symptomatic COVID-19 positive adults recruited from 12 public health clinics across Brazil between March 23, 2021, and Aug. 6, 2021. Six hundred seventy-nine were prescribed ivermectin or a placebo, and the remaining 2,157 received another intervention.
Overall, 100 patients in the ivermectin group and 111 in the placebo group had a primary-outcome event, defined as either a hospital admission or a prolonged emergency department visit. Of the 211 primary-outcome events, 171 were hospital admissions. There were no significant effects of ivermectin on secondary outcomes or adverse events.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
